Wanbury Share Price Today | Stock Price & Wanbury Share Screener
As of October 5, 2026, the live Wanbury share price (NSE: WANBURY) is ₹190.46 on NSE and ₹189.30 on BSE, down 3.80% from the previous close, with shares trading between ₹187.00 and ₹198.99 in today's trading session, and a 52-week range of ₹163.34–₹344.75. Check WANBURY 52-week high low for the annual price range and momentum. Use the Wanbury stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Wanbury opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹164 and net income of ₹14, with EBITDA of ₹25, an operating margin of 15.0% and a profit margin of 8.5%.
Wanbury Share Price Chart
Track the current stock price of Wanbury with an interactive chart. Analyse WANBURY share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Wanbury stock quote in one place.
The quote of ₹190.46 sits between the 52-week low of ₹163.34 and the 52-week high of ₹344.75, and the latest session moved -3.80% from the previous close.
Wanbury Company Profile - Fundamental Screener
Screen Wanbury company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for WANBURY shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE107F01022.
Company Details
Classification
Identifiers and Leadership
Wanbury Balance Sheet Screener
Screen WANBURY balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹414, up from ₹344 in 2024.
Latest statistics put total assets at ₹414 and shareholder funds at ₹59, with a leverage ratio of 3.38.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 414 | 344 | 304 | 353 | 289 | 279 | 286 | 273 | 412 | 388 |
| Current Assets | 193 | 159 | 122 | 171 | 98 | 90 | 94 | 74 | 192 | 164 |
| Fixed Assets | 201 | 167 | 167 | 167 | 167 | 164 | 172 | 178 | 186 | 180 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 180 | 101 | 16 | 16 | 90 | 111 | 134 | 109 | 163 | 251 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 59 | 28 | -33 | -23 | -156 | -144 | -209 | -185 | -153 | -162 |
| Share Capital | 33 | 33 | 33 | 33 | 25 | 25 | 24 | 24 | 23 | 20 |
| Reserves & Surplus | 21 | -11 | -66 | -56 | -181 | -168 | -233 | -208 | -177 | -221 |
Wanbury Income Statement Screener - Profit & Revenue Analysis
Screen Wanbury income statement and profit fundamentals. Analyze WANBURY quarterly results. Wanbury reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2025-Jun, revenue was ₹164 and net profit was ₹14, equal to earnings per unit of ₹4.12, at an operating margin of 15%.
In that period expenses were ₹139, interest cost ₹8 and tax ₹0. The next period listed, 2025-Mar, shows revenue of ₹174 and net profit of ₹20.
| Item | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar | 2021-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 164 | 174 | 134 | 163 | 132 | 166 | 146 | 145 | 147 | 131 | 126 | 125 | 119 | 211 | 125 |
| Expenses | 139 | 142 | 120 | 141 | 120 | 121 | 124 | 127 | 133 | 119 | 119 | 118 | 120 | 122 | 116 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 25 | 32 | 15 | 22 | 12 | 45 | 22 | 18 | 14 | 12 | 7 | 6 | -1 | 90 | 9 |
| Operating Profit % | 15.00% | 17.00% | 10.00% | 12.00% | 8.00% | 13.00% | 15.00% | 12.00% | 9.00% | 10.00% | 5.00% | 5.00% | -3.00% | 10.00% | 7.00% |
| Depreciation | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 8 | 9 | 10 | 10 | 8 | 8 | 8 | 8 | 6 | 8 | 7 | 4 | 3 | 5 | 6 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 14 | 19 | 1 | 8 | 1 | 34 | 10 | 7 | 5 | 1 | -3 | -1 | -7 | 82 | 0 |
| Tax | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Net Profit | 14 | 20 | 1 | 8 | 1 | 34 | 10 | 7 | 5 | 1 | -3 | -1 | -7 | 83 | 0 |
| EPS | 4.12 | 6.18 | 0.38 | 2.44 | 0.32 | 10.28 | 3.14 | 2.25 | 1.43 | 0.31 | -1.00 | -0.27 | -2.22 | 25.62 | 0.12 |
Wanbury Cash Flow Screener - Liquidity Fundamentals
Screen WANBURY cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹26, and net cash flow was an inflow of ₹1.
Over the same period, investing activities used ₹51 and financing activities provided ₹26.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 26 | 4 | 20 | 41 | 17 | 44 | 30 | 33 | 43 | 43 |
| Investing Activities | -51 | -17 | -9 | 1 | 8 | 64 | -3 | -1 | -13 | -20 |
Financing and Net Cash | ||||||||||
| Financing Activities | 26 | 15 | -32 | -29 | -17 | -108 | -27 | -33 | -27 | -28 |
| Net Cash Flow | 1 | 2 | -21 | 13 | 7 | 0 | 0 | -2 | 3 | -5 |
Wanbury Shareholding Pattern Screener
See Wanbury shareholding pattern with promoter, FII, and DII holdings. Check Wanbury promoter holding and ownership changes for WANBURY on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 43.02%, foreign institutions 0.59%, domestic institutions 0.00% and the public 42.17%, spread across 16,732 shareholders.
The shareholder count was 16,732 in 2026-Mar, compared with 17,174 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 43.02% | 43.02% | 39.76% | 39.63% | 43.09% | 43.07% | 39.79% | 39.79% |
Institutional Investors | ||||||||
| FII Holding | 0.59% | 0.89% | 1.55% | 1.59% | 0.82% | 0.72% | 0.18% | 0.22% |
| DII Holding | 0.00% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 42.17% | 41.91% | 41.78% | 42.06% | 41.19% | 41.28% | 41.81% | 41.42% |
| Other Holding | 14.23% | 14.12% | 16.90% | 16.71% | 14.89% | 14.92% | 18.22% | 18.57% |
| Shareholder Count | 16,732 | 17,174 | 17,889 | 17,894 | 17,717 | 17,261 | 13,087 | 14,400 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Wanbury. Wanbury dividend yield can be compared with peers and other stocks in the market.
Wanbury Stock Index Membership - Nifty & Sensex
See which indices include Wanbury stock. Check WANBURY index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Wanbury Market Events Screener - Corporate Actions
Get Wanbury corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Wanbury stock events that may affect WANBURY share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 24, 2026, with a record date of September 24, 2026.
It is followed by Quarterly Result Announcement dated August 11, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-24 | 2026-09-24 | Annual General Meeting | NA | -9.39% |
| 2026-08-11 | 2026-08-11 | Quarterly Result Announcement | NA | -16.19% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 19.19% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 58.03% |
| 2026-01-05 | 2026-01-05 | Extraordinary General Meeting | NA | 0.94% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -9.05% |
| 2025-09-18 | 2025-09-18 | Annual General Meeting | NA | -12.35% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | 10.17% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 11.60% |
| 2025-02-20 | 2025-02-20 | Extraordinary General Meeting | NA | -25.74% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -12.40% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 10.56% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | 15.79% |
| 2023-09-27 | 2023-09-27 | Annual General Meeting | NA | 27.65% |
| 2023-08-21 | 2023-08-21 | Extraordinary General Meeting | NA | 3.28% |
Wanbury Competitors Screener - Peer Stocks Comparison
Screen WANBURY competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Wanbury Company Announcements - News & Reports Screener
Screen WANBURY latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 27, 2026 and September 26, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Closure of Trading Window | - |
| 2026-09-27 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-26 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-26 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM). | - |
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-31 | Annual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited. | - |
| 2026-08-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-11 | Financial Results For The First Quarter Ended 30Th June 2026 | - |
| 2026-08-11 | Board Meeting Outcome for Outcome Of The Board Meeting Held On August 11 2026 | - |
| 2026-08-03 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-22 | Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Companys Facility At Tanuku West Godavari District Andhra Pradesh | - |
| 2026-07-20 | Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Companys Facility At Tanuku West Godavari District Andhra Pradesh | - |
| 2026-07-17 | Clarification On Price Movement | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹190.46, within a 52-week range of ₹163.34 to ₹344.75. The P/E ratio is 16.18 and the P/B ratio is 8.98, with earnings per unit of ₹9.32. Market capitalisation stands at ₹692.31 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.